BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38531062)

  • 1. Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
    Zinzani PL; Salles G; Moskowitz AJ; Santoro A; Mehta A; Barr PM; Mehta-Shah N; Collins GP; Ansell SM; Brody JD; Domingo-Domenech E; Johnson NA; Cunningham D; Ferrari S; Lisano J; Krajewski J; Wen R; Akyol A; Crowe R; Savage KJ
    Blood Adv; 2024 May; 8(10):2400-2404. PubMed ID: 38531062
    [No Abstract]   [Full Text] [Related]  

  • 2. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study.
    Dummer R; Prince HM; Whittaker S; Horwitz SM; Kim YH; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Eradat H; Pinter-Brown L; Sanches JA; Ortiz-Romero PL; Akilov OE; Geskin L; Huen A; Walewski J; Wang Y; Lisano J; Richhariya A; Feliciano J; Zhu Y; Bunn V; Little M; Zagadailov E; Dalal MR; Duvic M
    Eur J Cancer; 2020 Jul; 133():120-130. PubMed ID: 32502876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
    Shea L; Mehta-Shah N
    Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of Brentuximab Vedotin in advanced cutaneous T-Cell lymphomas patients.
    Papadavid E; Kapniari E; Marinos L; Nikolaou V; Oikonomidi A; Georgakopoulos J; Stratigos A; Kouloulias V; Pappa V
    J Eur Acad Dermatol Venereol; 2019 May; 33(5):e223-e225. PubMed ID: 30821007
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of brentuximab vedotin plus bendamustine in advanced-stage primary cutaneous T-cell lymphomas.
    Dumont M; Ram-Wolff C; Roelens M; Brice P; Peffault de Latour R; Battistella M; Madelaine I; Delyon J; Herms F; Bouaziz JD; Moins-Teisserenc H; Lebbé C; Bagot M; de Masson A
    Br J Dermatol; 2019 Dec; 181(6):1315-1317. PubMed ID: 31206589
    [No Abstract]   [Full Text] [Related]  

  • 6. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
    Vu K; Wu CH; Yang CY; Zhan A; Cavallone E; Berry W; Heeter P; Pincus L; Wieduwilt MJ; William BM; Andreadis C; Kaplan LK; McCormick F; Porcu P; Brammer JE; Ai WZ
    Clin Cancer Res; 2020 Mar; 26(5):1000-1008. PubMed ID: 31772119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin.
    Goyal A; Patel S; Goyal K; Morgan EA; Foreman RK
    J Cutan Pathol; 2019 Nov; 46(11):823-829. PubMed ID: 31286556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.
    Diefenbach CS; Hong F; Ambinder RF; Cohen JB; Robertson MJ; David KA; Advani RH; Fenske TS; Barta SK; Palmisiano ND; Svoboda J; Morgan DS; Karmali R; Sharon E; Streicher H; Kahl BS; Ansell SM
    Lancet Haematol; 2020 Sep; 7(9):e660-e670. PubMed ID: 32853585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Brentuximab Vedotin Versus Physician's Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada.
    Elsea D; Savage KJ; Lilley C; Lisano J; Liu J; Yu KS
    Adv Ther; 2023 May; 40(5):2326-2338. PubMed ID: 36920744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives.
    Prince HM; Hutchings M; Domingo-Domenech E; Eichenauer DA; Advani R
    Ann Hematol; 2023 Jan; 102(1):13-29. PubMed ID: 36512081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
    O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
    Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.
    Cheson BD; Bartlett NL; LaPlant B; Lee HJ; Advani RJ; Christian B; Diefenbach CS; Feldman TA; Ansell SM
    Lancet Haematol; 2020 Nov; 7(11):e808-e815. PubMed ID: 33010817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.
    Herrera AF; Chen L; Nieto Y; Holmberg L; Johnston P; Mei M; Popplewell L; Armenian S; Cao T; Farol L; Sahebi F; Spielberger R; Chen R; Nademanee A; Puverel S; Nwangwu M; Lee P; Song J; Skarbnik A; Kennedy N; Peters L; Rosen ST; Kwak LW; Forman SJ; Feldman T
    Lancet Haematol; 2023 Jan; 10(1):e14-e23. PubMed ID: 36403579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of brentuximab-vedotin and ifosfamide, carboplatin, etoposide in relapsed/refractory peripheral T-cell lymphoma.
    Van de Wyngaert Z; Coppo P; Cervera P; Fabiani B; Lemonnier MP; Corre E; Marjanovic Z; Aoudjhane M; Mohty M; Duléry R
    Eur J Haematol; 2021 Apr; 106(4):467-472. PubMed ID: 33320379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term survival, time to next treatment and CD30 expression in patients with advanced CD30
    Gosmann J; Stadler R
    J Dtsch Dermatol Ges; 2022 Apr; 20(4):514-517. PubMed ID: 35319153
    [No Abstract]   [Full Text] [Related]  

  • 16. Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study.
    Zinzani PL; Santoro A; Gritti G; Brice P; Barr PM; Kuruvilla J; Cunningham D; Kline J; Johnson NA; Mehta-Shah N; Manley T; Francis S; Sharma M; Moskowitz AJ
    J Clin Oncol; 2019 Nov; 37(33):3081-3089. PubMed ID: 31398081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brentuximab vedotin in the treatment of relapsed/refractory CD30+ peripheral T-cell lymphoma: A FIL phase 2 study.
    Stefoni V; Pellegrini C; Argnani L; Corradini P; Dodero A; Orsucci L; Volpetti S; Zinzani PL
    Hematol Oncol; 2022 Apr; 40(2):307-309. PubMed ID: 35023190
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma.
    Gentille C; Sarfraz H; Joshi J; Randhawa J; Shah S; Pingali SR
    Cancer Rep (Hoboken); 2022 Jul; 5(7):e1581. PubMed ID: 35263030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Composite diffuse large B-cell and peripheral T-cell lymphoma with T-helper phenotype treated with both rituximab and brentuximab vedotin.
    Ohya K; Okuyama S; Ogata SY; Maeda K; Yamada K; Ohshima K; Tajima K
    Ann Hematol; 2021 Nov; 100(11):2873-2875. PubMed ID: 34427738
    [No Abstract]   [Full Text] [Related]  

  • 20. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
    Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
    Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.